DHR · News · 20260726N
Guidance / Outlook
DANAHER CORP /DE/ · 2026-07-26 · Importance 62 · Surprise 68 · No source text
Danaher’s third-party-reported outlook calls for Q3 2026 revenue growth of 2%–3%, reflecting a headwind in respiratory testing. The company reportedly expects high-single-digit growth in its bioprocessing business despite ongoing market concerns. The outlook indicates near-term pressure in Diagnostics may offset stronger Biotechnology demand during the quarter.
Key facts
- Danaher provided modest Q3 revenue guidance of 2-3% due to a respiratory testing headwind. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | +1.3% | Danaher provided modest Q3 revenue guidance of 2-3% due to a respiratory testing headwind. |